Peterson Wealth Services Buys 453 Shares of Edwards Lifesciences Co. (NYSE:EW)

Peterson Wealth Services increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 10.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,783 shares of the medical research company’s stock after acquiring an additional 453 shares during the quarter. Peterson Wealth Services’ holdings in Edwards Lifesciences were worth $354,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Stonebridge Financial Group LLC purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $195,000. Focus Financial Network Inc. purchased a new stake in Edwards Lifesciences in the 4th quarter worth approximately $206,000. Equitable Trust Co. lifted its holdings in Edwards Lifesciences by 10.9% in the 4th quarter. Equitable Trust Co. now owns 73,042 shares of the medical research company’s stock worth $5,407,000 after buying an additional 7,154 shares during the period. Ferguson Wellman Capital Management Inc. lifted its holdings in Edwards Lifesciences by 2.7% in the 4th quarter. Ferguson Wellman Capital Management Inc. now owns 27,692 shares of the medical research company’s stock worth $2,050,000 after buying an additional 718 shares during the period. Finally, Birch Hill Investment Advisors LLC lifted its holdings in Edwards Lifesciences by 90.3% in the 4th quarter. Birch Hill Investment Advisors LLC now owns 738,779 shares of the medical research company’s stock worth $54,692,000 after buying an additional 350,650 shares during the period. 79.46% of the stock is currently owned by institutional investors.

Edwards Lifesciences Stock Up 1.0 %

Edwards Lifesciences stock opened at $71.05 on Tuesday. The firm has a market cap of $41.91 billion, a price-to-earnings ratio of 10.25, a PEG ratio of 3.64 and a beta of 1.10. The stock has a fifty day simple moving average of $72.45 and a two-hundred day simple moving average of $69.18. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06.

Insiders Place Their Bets

In related news, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the sale, the vice president now owns 23,189 shares of the company’s stock, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of Edwards Lifesciences stock in a transaction on Wednesday, November 13th. The stock was sold at an average price of $65.57, for a total value of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 8,000 shares of company stock valued at $547,430. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several research analyst reports. Canaccord Genuity Group increased their price objective on Edwards Lifesciences from $63.00 to $68.00 and gave the stock a “hold” rating in a report on Thursday, December 5th. Truist Financial reiterated a “hold” rating and issued a $78.00 price objective (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Royal Bank of Canada raised their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the company an “outperform” rating in a research note on Thursday, December 5th. Sanford C. Bernstein upgraded Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Finally, Robert W. Baird lowered their target price on Edwards Lifesciences from $73.00 to $68.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus price target of $79.19.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.